Rayner, a global manufacturer of products for cataract surgery headquartered in Worthing, UK, has appointed Scott Corning as Vice President, Americas.
Scott Corning
Mr Corning has 25 years of experience developing and driving successful brands and commercial teams within the ophthalmic pharmaceutical and medical device industries. As Senior Vice President, Commercial at Ocular Therapeutix, he contributed to company strategy and led their commercial effort. Prior to that, Mr Corning worked at Alcon in both the surgical and pharmaceutical divisions.
Mr Corning’s appointment comes during an exciting year of growth and development for Rayner, as it celebrates the recent implantation of the new RayOne Galaxy IOL – the world’s first spiral IOL – was in the United States Food and Drug Administration (FDA) approved Investigational Device Exemption (IDE) Study. If successful, the results of the study are intended to allow a Pre-Market Approval (PMA) submission to the FDA.
Rayner’s portfolio also includes Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3%, a product added to ophthalmic irrigating solutions to prevent intraoperative miosis, maintain pupil size, and reduce postoperative ocular pain.
